[1] Cautela J, Tartiere JM, Cohen-Solal A, et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. Eur J Heart Fail 2020; 22: 1357−1365. doi: 10.1002/ejhf.1835 [2] O’Connor C, Fiuzat M, Mulder H, et al. Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. Eur J Heart Fail 2019; 21: 770−778. doi: 10.1002/ejhf.1450 [3] Arundel C, Lam PH, Gill GS, et al. Systolic blood pressure and outcomes in patients with heart failure with reduced ejection fraction. J Am Coll Cardiol 2019; 73: 3054−3063. doi: 10.1016/j.jacc.2019.04.022 [4] Agostoni P, Paolillo S, Mapelli M, et al. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. Eur J Heart Fail 2018; 20: 700−710. doi: 10.1002/ejhf.989 [5] Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1574−1585. doi: 10.1002/ejhf.813 [6] Böhm M, Young R, Jhund PS, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J 2017; 38: 1132−1143. doi: 10.1093/eurheartj/ehw570 [7] Greene SJ, Fonarow GC, DeVore AD, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 2019; 73: 2365−2383. doi: 10.1016/j.jacc.2019.02.015 [8] Senni M, McMurray JJV, Wachter R, et al. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. Eur J Heart Fail 2018; 20: 491−500. doi: 10.1002/ejhf.1054 [9] Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 2018; 72: 351−366. doi: 10.1016/j.jacc.2018.04.070 [10] Desai AS, Solomon S, Claggett B, et al. Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF trial. Circ Heart Fail 2016; 9: e002735. doi: 10.1161/CIRCHEARTFAILURE.115.002735 [11] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993−1004. doi: 10.1056/NEJMoa1409077 [12] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145: e895−e1032. doi: 10.1161/CIR.0000000000001063 [13] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599−3726. doi: 10.1093/eurheartj/ehab368 [14] Wang C, Lin Z, Miao D, et al. Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study. ESC Heart Fail 2023; 10: 1961−1971. doi: 10.1002/ehf2.14367 [15] Wu AH, Lin ZW, Ji XP, et al. [Titration strategy of sacubitril/valsartan in patients with heart failure with reduced ejection fraction and hypotension]. Zhonghua Xin Xue Gu an Bing Za Zhi 2023; 51: 1098−1103. [In Chinese]. doi: 10.3760/cma.j.cn112148-20221222-01006 [16]

Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J He art Fail 2021; 23: 1040–1048.

[17]

Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019; 380: 1090.

[18] Peri-Okonny PA, Mi X, Khariton Y, et al. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry. JACC Heart Fail 2019; 7: 350−358. doi: 10.1016/j.jchf.2018.11.011 [19] Veenis JF, Brunner-La Rocca HP, Linssen GCM, et al. Treatment differences in chronic heart failure patients with reduced ejection fraction according to blood pressure. Circ Heart Fail 2020; 13: e006667. doi: 10.1161/CIRCHEARTFAILURE.119.006667 [20] Pandey AC, Jer D, Kuo RS, et al. Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: effects on N-terminal pro B-type natriuretic peptide levels. Clin Cardiol 2021; 44: 85−90. doi: 10.1002/clc.23509 [21] Kim H, Oh J, Lee S, et al. Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis. Sci Rep 2021; 11: 16335. doi: 10.1038/s41598-021-95787-w [22] Hu J, Wu Y, Zhou X, et al. Beneficial effects of sacubitril/valsartan at low doses in an Asian real-world heart failure population. J Cardiovasc Pharmacol 2020; 76: 445−451. doi: 10.1097/FJC.0000000000000873 [23] Kido K, Bianco C, Caccamo M, et al. Evaluating sacubitril/valsartan dose dependence on clinical outcomes in patients with heart failure with reduced ejection fraction. Ann Pharmacother 2021; 55: 1069−1075. doi: 10.1177/1060028020983522 [24] Corrado E, Dattilo G, Coppola G, et al. Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients. Eur J Clin Ph armacol 2022; 78: 19−25. doi: 10.1007/s00228-021-03210-0 [25] Chang HY, Feng AN, Fong MC, et al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol 2019; 74: 372−380. doi: 10.1016/j.jjcc.2019.03.010 [26] Rouleau JL, Roecker EB, Tendera M, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 2004; 43: 1423−1429. doi: 10.1016/j.jacc.2003.11.037 [27] Vardeny O, Claggett B, Kachadourian J, et al. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial. Circ Heart Fail 2018; 11: e004745. doi: 10.1161/CIRCHEARTFAILURE.117.004745 [28] Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019; 380: 539−548. doi: 10.1056/NEJMoa1812851 [29] Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J He art Fail 2019; 21: 998−1007. doi: 10.1002/ejhf.1498 [30] Rosano GMC, Moura B, Metra M, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2021; 23: 872−881. doi: 10.1002/ejhf.2206 [31] Ameri P, Bertero E, Maack C, et al. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?. Eur Heart J Cardiov asc Pharmacother 2021; 7: 539−546. doi: 10.1093/ehjcvp/pvab033